DDrare: Database of Drug Development for Rare Diseases

7. 大脳皮質基底核変性症
［臨床試験数：16，薬物数：33（DrugBank：11），標的遺伝子数：6，標的パスウェイ数：13］

Searched query = "Corticobasal degeneration", "Corticobasal syndrome", "CBD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; ABBV-8E12; AL; Anti-Parkinson medication; BIIB092; BOTULINUM TOXIN TYPE A; Botulinum toxin type A; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Dopamine; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Leucine; Lithium; NT 101; Other: 13C6 Leucine; Procedure: Brain PET scan; Raclopride; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Vizamyl; Vizamyl (flutemetamol(F-18)); Xeomin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01056965 (ClinicalTrials.gov)	January 2010	21/1/2010	Davunetide (AL-108) in Predicted Tauopathies - Pilot Study	A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies	Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia	Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray	University of California, San Francisco	NULL	Completed	40 Years	85 Years	All	12	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01056965
(ClinicalTrials.gov)

January 2010

21/1/2010

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies

Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia

Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray

University of California, San Francisco

NULL

Completed

40 Years

85 Years

All

Phase 1

United States